The companies aim to expand diagnostic insights for patients prescribed Kestra’s Assure wearable cardioverter defibrillator (WCD). Their agreement includes an exclusive license and co-development arrangement, plus a $5 million equity investment in Biobeat’s Series B.
Kirkland, Washington–based Kestra develops the Assure wearable cardioverter defibrillator (WCD), which provides autonomous detection and defibrillation for ventricular arrhythmias. It can also detect and record other clinically significant arrhythmias.
Biobeat develops an FDA-cleared “patch” device for blood pressure measurement. It can record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters. Those include continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output.
The companies plan to integrate Biobeat’s technology into its product portfolio to make ABPM data available for patients using Assure.
Commentary from Kestra and Biobeat officials
Brian Webster, President and CEO of Kestra, said:
“Health care providers have consistently told us that better visibility to blood pressures during cardiac recovery would meaningfully support clinical decision making. This collaboration allows us to expand the clinical insights available during recovery while reinforcing ASSURE as a flexible platform designed to support at-home patient care.”
Arik Ben Ishay, CEO of Biobeat, said:
“Kestra has built a scalable platform focused on protecting and supporting patients during cardiac recovery. We are excited to collaborate with Kestra as they explore how our FDA-cleared, 24-hour blood pressure monitoring for hypertension diagnosis may complement their Cardiac Recovery System® platform and expand the clinical insights available to care teams managing complex cardiac patients.”
